CoChat

The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function

Open access
Wan, Lixin, Chen, Ming, Cao, Juxiang, Dai, Xiangpeng, Yin, Qing, Zhang, Jinfang, Song, Su-Jung, Lu, Ying, Liu, Jing, Inuzuka, Hiroyuki, Katon, Jesse M., Berry, Kelsey, Fung, Jacqueline, Ng, Christopher, Liu, Pengda, Song, Min Sup, Xue, Lian, Bronson, Roderick T., Kirschner, Marc W., Cui, Rutao, Pandolfi, Pier Paolo, Wei, Wenyi · 2017 · Cancer Discovery
Cited by 74

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BRAF drives tumorigenesis by coordinating the activation of the RAS/RAF/MEK/ERK oncogenic signaling cascade. However, upstream pathways governing BRAF kinase activity and protein stability remain undefined. Here, we report that in primary cells with active APCFZR1, APCFZR1 earmarks BRAF for ubiquitination-mediated proteolysis, whereas in cancer cells with APC-free FZR1, FZR1 suppresses BRAF through disrupting BRAF dimerization. Moreover, we identified FZR1 as a direct target of ERK and CYCLIN D1/CDK4 kinases. Phosphorylation of FZR1 inhibits APCFZR1, leading to elevation of a cohort of oncogenic APCFZR1 substrates to facilitate melanomagenesis. Importantly, CDK4 and/or BRAF/MEK inhibitors restore APCFZR1 E3 ligase activity, which might be critical for their clinical effects. Furthermore, FZR1 depletion cooperates with AKT hyperactivation to transform primary melanocytes, whereas genetic ablation of Fzr1 synergizes with Pten loss, leading to aberrant coactivation of BRAF/ERK and AKT signaling in mice. Our findings therefore reveal a reciprocal suppression mechanism between FZR1 and BRAF in controlling tumorigenesis. Significance: FZR1 inhibits BRAF oncogenic functions via both APC-dependent proteolysis and APC-independent disruption of BRAF dimers, whereas hyperactivated ERK and CDK4 reciprocally suppress APCFZR1 E3 ligase activity. Aberrancies in this newly defined signaling network might account for BRAF hyperactivation in human cancers, suggesting that targeting CYCLIN D1/CDK4, alone or in combination with BRAF/MEK inhibition, can be an effective anti-melanoma therapy. Cancer Discov; 7(4); 424–41. ©2017 AACR. See related commentary by Zhang and Bollag, p. 356. This article is highlighted in the In This Issue feature, p. 339

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-16-0647

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 74

Metadata

Authors
Wan, L., Chen, M., Cao, J., Dai, X., Yin, Q., Zhang, J., Song, S.-J., Lu, Y., Liu, J., Inuzuka, H., Katon, J. M., Berry, K., Fung, J., Ng, C., Liu, P., Song, M. S., Xue, L., Bronson, R. T., Kirschner, M. W., Cui, R., Pandolfi, P. P., & Wei, W.
Venue
Cancer Discovery
Published
2017-04-01
Volume
7
Issue
4
Pages
424-441
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2586090195
Cited by
74
References
17
FWCI
3.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. https://app.cochat.ai/papers/10.1158/2159-8290.cd-16-0647
The paper
Wan, L., Chen, M., Cao, J., Dai, X., Yin, Q., Zhang, J., Song, S.-J., Lu, Y., Liu, J., Inuzuka, H., Katon, J. M., Berry, K., Fung, J., Ng, C., Liu, P., Song, M. S., Xue, L., Bronson, R. T., Kirschner, M. W., . . . Wei, W. (2017). The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-16-0647

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.